Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results

d, (8) receive required regulatory approvals, (9) successfully conduct clinical trials in a timely manner, (10) establish its competitive position for its products, (11) develop and commercialize products that are superior to existing or newly developed competitor products, (12) develop products without any defects, (13) have sufficient capital resources to fund its operations, (14) protect its intellectual property rights and patents, (15) implement its sales and marketing strategy, (16) successfully attract and retain collaborative partners, (17) successfully commercialize and gain market acceptance for its Keflex products, (18) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (19) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.




Three Months Ended Sept 30, Nine Months Ended Sept 30,

2007 2006 2007 2006

Product sales $3,144,532 $2,369,975 $7,598,127 $3,566,563

Costs and


Cost of product

sales 1,183,772 440,159 1,864,643 517,765

Research and

development 5,509,093 5,737,047 18,485,164 19,700,263

Selling, general

and administrative 6,475,742 6,069,529 20,473,947 13,001,312


expenses 13,168,607 12,246,735 40,823,754 33,219,340

Loss from


SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... , LYNBROOK, N.Y., Sept. 16 ... a biopharmaceutical company developing first-in-class collagenase-based products, today announced ... Food and Drug Administration,s (FDA) unanimously recommended by a ... histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing ...
... published online today [Thursday] estimates nearly 45,000 annual deaths are ... two and a half times higher than an estimate from ... study, "Health Insurance and Mortality in U.S. Adults," appears in ... Public Health . The Harvard-based researchers found that uninsured, ...
... , SAN FRANCISCO, Sept. 21 Medithrive, Inc., ... its state of the art dispensary, offering patients a beautiful ... of medicinal marijuana products. , , ... 16th, in San Francisco, CA, has positioned itself as the ...
... post-menopausal women with early breast cancer to the drug exemestane ... keeping them on tamoxifen for five years improves the chance ... for at least the next six years. "These ... mid-way through the five-year tamoxifen treatment plan provides a clear ...
... CINCINNATICancer predisposition resulting from the presence of a ... researchers at the University of Cincinnati (UC) have ... risk for development of cancer in individuals harboring ... a result of environmental exposure. Peter Stambrook, PhD, ...
... NEW YORK, Sept. 21 In a bid ... online auction of the Ysio Digital Radiology System. As the ... N.Y., presented them a check for $285,309. , , ... , , , ...
Cached Medicine News:Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 2Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 3Health News:45,000 excess deaths annually linked to lack of health insurance: Harvard study 2Health News:Switching early breast cancer patients to exemestane improves long-term survival 2Health News:Cancer predisposition from genetic variation shows strong gender bias 2
(Date:1/15/2014)... 2014  Research and Markets ( ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: ) ... patients in order to treat dental impairments, for tooth ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... 9, 2012 SciVerse Hub, SciVerse Applications, ... Sciences Recognized for Innovation and Achievement ... medical information products and services, today announced that it ... American Publishers Awards for Professional and Scholarly Excellence (the ...
... SAN DIEGO, Feb. 9, 2012  Volcano Corporation (NASDAQ: ... precision guided therapy tools designed to enhance the diagnosis ... announced it will report its operating results for the ... The company will hold a conference call ...
Cached Medicine Technology:Elsevier Honored With Six PROSE Awards 2Elsevier Honored With Six PROSE Awards 3Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast 2
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
... Our most popular onsite test! QuickScreen™ ... the urine sample, and your choice of ... QuickScreen™ multi-panels offer total flexibility for your ... into the specimen and the built-in timer ...
... products, SEDIPLAST® is a completely closed ... protect laboratory personnel from the risk ... a uniquely designed erythrocyte sedimentation rate ... and convenience as well as reliable ...
... guaiac as a test for the presence of ... compounds present in guaiac to quinones, resulting in ... is present, the heme portion of the hemoglobin ... the release of oxygen from hydrogen peroxide which ...
Medicine Products: